EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy

Noemi Bachmeier-Zbären, Alper Celik, Robin van Brummelen, Nadine Roos, Melanie Steinmann, Jennifer A Hoang iD, Xiaojun Yin, Christina M Ditlof, Lucy Duan, Julia E M Upton iD, Thomas Kaufmann iD, Alexander Eggel iD und 2 weitere

Allergy · 2025-01 · 80 (1) · 215-226

DOI: 10.1111/all.16341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 28.09.2024. Verfasst von Noemi Bachmeier-Zbären und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Mast Cells, Homeodomain Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Food Allergy and Anaphylaxis Program at the Hospital for Sick Children, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Innosuisse - Schweizerische Agentur für Innovationsförderung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peanut allergy is among the most severe and common food allergies. The diagnosis has a significant impact on the quality of life for patients and their families. An effective management approach depends on accurate, safe, and easily implementable diagnostic methods. We previously developed a cell‐based assay using Hoxb8 mast cells (Hoxb8 MCs) aimed at improving clinical allergy diagnosis. In this study, we assessed its diagnostic performance by measuring blinded sera from a prospectively enrolled and pre‐validated peanut allergy cohort.

Methods

Hoxb8 MCs were passively sensitized with sera from peanut‐allergic and peanut tolerant children and adolescents ( n = 112). Degranulation of Hoxb8 MCs was quantified upon stimulation with dose‐titrated peanut extract by means of flow cytometry, using CD107a as activation marker. The results from the Hoxb8 mast cell activation test (Hoxb8 MAT) were compared to established diagnostic assays such as the skin prick test (SPT), specific IgE (sIgE) levels, and the basophil activation test (BAT). Additionally, serum samples from BAT nonresponders were assessed with the Hoxb8 MAT.

Results

Hoxb8 MAT displayed a robust dose‐dependent activation to peanut extract, with a cutoff value of ≤5.2% CD107a positive cells. The diagnostic accuracy was highest at allergen concentrations ≥100 ng/mL, with an area under the receiver operating characteristic curve (AUROC) of 0.97, 93% sensitivity, and 96% specificity, outperforming traditional SPT and sIgE tests. When compared to BAT, Hoxb8 MAT exhibited comparable diagnostic efficacy. Moreover, sera from BAT nonresponders were accurately classified into allergics and nonallergics by the Hoxb8 MAT.

Conclusions

The Hoxb8 MAT demonstrated a very good diagnostic precision in patients prospectively assessed for peanut allergy comparable to the fresh whole blood‐based BAT. Additionally, it demonstrated its value for accurate classification of BAT nonresponders into allergic and nonallergic individuals. Further investigations into its utility in the routine clinical setting are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityMast CellsHomeodomain ProteinsHumansChildAdolescentFemaleMaleChild, PreschoolImmunoglobulin EAllergensCell DegranulationSkin TestsSensitivity and SpecificityInfant

Stichwörter der Autor:innen

Hoxb8 mast cell activation testbasophil activation testoral food challengepeanut allergy diagnosisspecific IgE

Substanzen

Immunoglobulin EHomeodomain ProteinsAllergens

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.
  • Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Department for BioMedical Research, Lung Precision Medicine (LPM), University of Bern, Bern, Switzerland.
  • Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.

ORCID-Profile: Jennifer A Hoang, Julia E M Upton, Thomas Kaufmann, Alexander Eggel, Thomas Eiwegger

Förderung

  • Food Allergy and Anaphylaxis Program at the Hospital for Sick Children
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Innosuisse - Schweizerische Agentur für Innovationsförderung

Zitieren

APA

Bachmeier-Zbären, N., Celik, A., van Brummelen, R., Roos, N., Steinmann, M., Hoang, J. A., Yin, X., Ditlof, C. M., Duan, L., Upton, J. E. M., Kaufmann, T., Eggel, A., Eiwegger, T., & MONAS working group (2025). Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy. Allergy, 80(1), 215-226. https://doi.org/10.1111/all.16341

Vancouver

Bachmeier-Zbären N, Celik A, van Brummelen R, Roos N, Steinmann M, Hoang JA, et al. Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy. Allergy. 2025;80(1):215-226. doi:10.1111/all.16341

BibTeX
@article{BachmeierZbren2025,
  author = {Bachmeier-Zbären, Noemi and Celik, Alper and van Brummelen, Robin and Roos, Nadine and Steinmann, Melanie and Hoang, Jennifer A and Yin, Xiaojun and Ditlof, Christina M and Duan, Lucy and Upton, Julia E M and Kaufmann, Thomas and Eggel, Alexander and Eiwegger, Thomas and MONAS working group, MONAS working group},
  title = {Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {1},
  pages = {215--226},
  doi = {10.1111/all.16341}
}
Kostenlos starten →